Revise, Edit, Delete: Gene Editing for a Healthier Future
What if we could remove diseases at the cellular level to stop them from growing before they begin?
Specific Biologics, a JLABS @ Toronto company recently selected as one of the first BLUE KNIGHT™ companies, is aiming to do just that.
Brent Stead, CEO, of Specific Biologics, presents on how the company’s gene editing platform technology differs from the well-known CRISPR-Cas9, and could more accurately correct errors at the genetic level in cells inside the body.
This program is part of BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA).
Please note that this webinar was originally run on October 13, 2020.
You are watching a rebroadcast of the webinar. There will not be a live Q&A session following the presentation. If you have any questions for the speakers, please email [email protected]
DISCLAIMER: The information on this webpage, including in the videos, is proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (“JJI”) and is for informational purposes only. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson or its affiliates. The information presented in the videos is specific and applicable to region in which the original presentation took place. Many videos contain information from, or sessions given by, third parties. Please note that only those third parties that provide this information are responsible for it. By providing this information, JJI does not endorse these third parties or any of the information provided in these videos, and JJI makes no representations, warranties, or assurances, express or implied, as to the content or the information presented and is not responsible for any use of this information by you.